Unfortunately, all biological drugs used in IBD, including monoclonal anti-TNF-α, present a primary non-response in approximately one third of cases and a secondary loss of response in another third of cases (10–20% per year). The gene discussed is TNF; the disease is inflammatory bowel disease.